Gabelli Commercial Aerospace and Defense ETF (ARCA: GCAD)

Ultime notizie per Gabelli Commercial Aerospace and Defense ETF (ARCA:GCAD)

Industrials

Technology

Consumer Cyclical

Other

The Fund will seek to achieve its investment objective by investing, under normal market conditions, at least 80% of its net assets in income producing equity securities including securities in the aerospace and defense sectors. Aerospace companies include manufacturers, assemblers and distributors of aircraft and aircraft parts. Defense companies include producers of components and equipment for the defense industry, such as military aircraft, radar equipment and weapons. Income producing equity securities include U.S. exchange-listed common stock and preferred stock. The Fund may also invest in foreign securities by investing in American Depositary Receipts. In making stock selections, the Adviser looks for securities that have a better yield than the average of the Standard and Poors 500 Index, as well as capital gains potential.

Spirit Aerosystems, Inc.

Boeing Company (The) Common Stock

Moog Inc

Ducommun Inc

Honeywell International Inc.

Lockheed Martin Corp

Textron

Curtiss Wright Corp (cw)

Raytheon Co.

Northrop Grumman Corp.

Gabelli Commercial Aerospace and Defense Fund

Gabelli Commercial Aerospace and Defense ETF

Keybanc analyst John Vinh maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Overweight and lowers the price target from $60 to $54.

News

Price Target

Analyst Ratings

LSCC

Keybanc Maintains Overweight on Lattice Semiconductor, Lowers Price Target to $54

Baird analyst David Koning maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Neutral and raises the price target from $92 to $94.

Baird Maintains Neutral on Fidelity National Info, Raises Price Target to $94

Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.20 by 80 percent. This is a 350 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $206.00 million which beat the analyst consensus estimate of $193.80 million by 6.30 percent. This is a 17.06 percent increase over sales of $175.99 million the same period last year.

Earnings

Earnings Beats

LIND

Lindblad Expeditions Q3 2024 GAAP EPS $0.36 Beats $0.20 Estimate, Sales $206.00M Beat $193.80M Estimate

In 2018, the International Brotherhood of Electrical Workers Local 38 Health and Welfare Fund and some consumers filed a proposed class action lawsuit against Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
The plaintiffs <a target="_blank" href="https://cases.justia.com/federal/district-courts/illinois/ilndce/1:2017cv02246/338055/91/0.pdf?ts=1520678017" rel="noreferrer noopener">alleged</a> that the retail pharmacy engaged in deceptive pricing practices through its Prescription Savings Club (PSC)—a program offering discounted prices on generic drugs for customers who pay without insurance.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41366045/walgreens-boots-alliance-analysts-expect-strategic-plans-will-boost-investor-confid" rel="noreferrer noopener">Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025</a>
Plaintiffs claim these practices led Walgreens to inflate the &#8220;usual and customary&#8221; (U&amp;C) prices reported to health insurers and third-party payors, resulting in customers overpaying for generic drugs.
Reuters noted that Walgreens&nbsp;has agreed to pay $100 million to settle a proposed class action lawsuit.
Reuters cited a Walgreens spokesperson and noted that the company accepts no liability and maintains that these claims are without merit.
Walgreens introduced its Prescription Savings Club (PSC) in 2007, offering over 500 commonly prescribed generic medications at reduced prices: $5, $10, or $15 for 30-day supplies, and $10, $20, or $30 for 90-day supplies, depending on the drug&#8217;s tier. Enrollment in the PSC requires a yearly fee of $20 for individuals or $30 per family.
The complaint asserts that while Walgreens offered these lower PSC prices to cash-paying customers, it charged higher prices for the same drugs to customers using private insurance, Medicare, or Medicaid. According to the plaintiffs, Walgreens&#8217; PSC prices should have been reported as its U&amp;C prices.
Instead, by reporting higher-than-PSC prices as U&amp;C prices on reimbursement claims, Walgreens allegedly engaged in a hidden dual-pricing scheme for drugs listed under the PSC.
Price Action: At last check Tuesday, WBA stock was up 0.21% at $9.35 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41739764/taiwan-semiconductor-faces-rising-energy-costs-potential-outages-threaten-production" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Legal

General

Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs

Barclays analyst George Wang initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight rating and announces Price Target of $91.

Initiation

Barclays Initiates Coverage On Celestica with Overweight Rating, Announces Price Target of $91

Guidance

NeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly sales of $805.86 million which missed the analyst consensus estimate of $809.30 million by 0.43 percent. This is a 0.23 percent increase over sales of $804.03 million the same period last year.

Earnings Misses

AHCO

AdaptHealth Q3 Sales $805.86M Miss $809.30M Estimate

Biotech

TRDA

Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_05112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
EURUSD remains poised around 1.0878 as markets brace for the outcome of the highly anticipated US presidential election. With the world watching, the direction of the major currency pair will hinge significantly on the election results, where a victory for Donald Trump is likely to bolster the USD, potentially leading to a notable increase. Conversely, a win for Kamala Harris could see the USD decline by an average of 1-2%.
The impending volatility is not solely due to the election but amplified by the upcoming Federal Reserve meeting scheduled for Wednesday. The Fed is anticipated to cut interest rates slightly by 25 basis points. Market participants are keenly awaiting any forward guidance from the Fed, particularly with expectations leaning towards another rate reduction in December.
While significant economic data releases are also expected, these pivotal events may overshadow their impact.
<h3>Technical Analysis Of EUR/USD</h3>
<a href="https://www.benzinga.com/files/u117641/eurusdh4_71.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh4_71.png" style="height:280px; width:624px" /></a>
The EURUSD market has completed a growth structure reaching 1.0913, considered part of a third growth wave targeting 1.0950. After this target is achieved, a retraction to 1.0860 is anticipated, potentially forming a broad consolidation range around this level. Technical indicators, such as the MACD, suggest an upward trajectory, reinforcing the possibility of reaching 1.0960 before a corrective pullback to 1.0860.
<a href="https://www.benzinga.com/files/u117641/eurusdh1_72.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh1_72.png" style="height:280px; width:624px" /></a>
Support at 1.0872 has spurred the development of a growth impulse towards 1.0900, which is expected to be tested soon. Breaching this level could extend the growth wave towards 1.0950. The Stochastic oscillator supports this short-term forecast, indicating upward momentum with its signal line targeting the upper echelons around 80.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Technicals

Forex

Markets

Trading Ideas

EUR/USD Stabilises As US Presidential Election Unfolds

Leerink Partners analyst Mani Foroohar initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $17.

CAMP

Leerink Partners Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $17

NURO

NeuroMetrix Reports Q3 2024 Sales Of $0.6M Vs. $1.2M YoY, With EPS Loss Of $(0.75) Compared To ($1.66) YoY

As of month-end, the Company operated approximately 185,000 bitcoin miners in data centers for both self-mining and hosting, representing a total energized hash rate of 21.8 EH/s. &nbsp;

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Says It Earned 369 Bitcoin In October From Its Owned Fleet Of Miners Vs. 345 In September

Select October 2024 Highlights
<ul>
<li>Record total average daily volume ("ADV") of $46.2 billion increased 40% compared to the prior year, and increased 2% compared to September 2024. These strong results were driven by total credit ADV of $15.0 billion, representing an increase of 19% compared to the prior year, and a decrease of 9% compared to September 2024. Record total rates ADV of $31.2 billion, which increased 54% compared to the prior year, and increased 9% compared to September 2024 levels, also contributed to the strong performance in October 2024.</li>
<li>Record total trading volume of $1.0 trillion on the platform increased 47% compared to the prior year, and increased 12% compared to September 2024.</li>
</ul>

MKTX

MarketAxess Announced Trading Volume For October 2024 With Total Average Daily Volume Of $46.2B, Up 40% YoY And +2% Compared To September 2024

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. The company reported quarterly sales of $167.824 million which beat the analyst consensus estimate of $167.010 million by 0.49 percent. This is a 10.44 percent increase over sales of $151.954 million the same period last year.

NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate

Leerink Partners analyst Christopher Liu downgrades IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowers the price target from $41 to $27.

Downgrades

IDYA

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27

Pseudonymous crypto analysts DonAlt and CryptoCred explored Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price trends and the impact of <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re">Tuesday&#8217;s presidential election</a>.
Bitcoin's Expected Trajectory
In the latest &#8216;Technical Roundup&#8217; <a href="https://www.youtube.com/watch?v=IhonU0vEFQE&amp;pp=ygURdGVjaG5pY2FsIHJvdW5kdXA%3D">episode</a>, DonAlt noted Bitcoin's recent surge to close to its all-time high before retreating below $70,000, calling the monthly close "catastrophic" after a key resistance retest.
He projected $49,000 as the first support level in the short term, with more robust support near $35,000 on a monthly timeframe, and in an extreme scenario, a possible drop to $16,000.
DonAlt attributes recent sluggish crypto market activity to positioning ahead of a potential Trump victory. He <a href="https://x.com/CryptoDonAlt/status/1853452002983813251">cautioned</a> on X that a Trump win might bring only modest short-term upside for Bitcoin, while a loss could trigger a sell-off, with a Harris win potentially causing an even steeper decline. Emphasizing flexibility, DonAlt highlighted the need for strategic preparation as election results unfold.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a>
Ethereum's Play
DonAlt also commented on Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance relative to Bitcoin, stressing the dependency of ETH/BTC strength on Bitcoin's movement. He shared his open position in a SOL/BTC trade.
Given the election uncertainty, DonAlt concluded, "I'm not going to trade in the next weeks, maybe months," stressing the importance of caution in the current environment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41709166/bitcoin-to-hit-100-000-by-january-2025-could-black-hole-effect-push-the-largest-crypto-to-">Bitcoin To Hit $100,000 By January 2025? Could &#8216;Black Hole Effect&#8217; Push The Largest Crypto To Never-Before-Seen Levels</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Veteran Traders Share 'Presidential Election Crypto Trading Roadmap,' Predict Heavy Volatility

<a href="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona" title="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona">https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona</a>

AMZN

Amazon Says Customers In West Valley Phoenix Metro Area Now Receiving Prime Air Drone Deliveries

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) reported quarterly earnings of $0.08 per share. This is unchanged from the same period last year. The company reported $1.02 billion in sales this quarter. This is a 12.64 percent increase over sales of $909.09 million the same period last year.

CLPBY

Coloplast Q4 EPS $0.08, Same YoY, Sales $1.02B Up From $909.09M YoY

RNAZ

Transcode Therapeutics Has Received Notice From The Nasdaq Stock Market To Grant Transcode's Request To Continue Its Listing On The Nasdaq Stock Market Subject To Certain Conditions To Regain Compliance

Comments

Gabelli Commercial Aerospace and Defense ETF

Notizie

Ultime notizie per Gabelli Commercial Aerospace and Defense ETF (ARCA:GCAD)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO